MetAL trial for prostate cancer

Bookmark and Share
Published: 1 Jul 2016
Views: 2058
Dr Mieke Van Hemelrijck - Kings College London, London, UK

Dr van Hemelrijck speaks with ecancertv at IARC 2016 about the conflicting results of metformin to treat prostate cancer.

Metformin, a widely available diabetes treatment, is variably associated with slowing or aggravating cancer, which may be due to the apparent protection from cancer associated with diabetes.

In a new trial, Dr van Hemelrijck aims to understand the mechanisms linking metformin, cancer and longevity with pre-surgical and post-operative sample analysis.